If you or someone you know is facing aplastic anemia, the medical procedures and management options range from urgent blood transfusions to potentially curative bone marrow transplants — and the right approach depends heavily on disease severity, patient age, and donor availability. This isn’t a one-size-fits-all condition. A 25-year-old with a matched sibling donor follows a completely different treatment path than a 65-year-old without one.
Aplastic anemia is a rare bone marrow failure syndrome affecting roughly 2–3 people per million annually in Western countries (higher in East Asia, around 5–7 per million). The marrow stops producing enough red blood cells, white blood cells, and platelets — a state called pancytopenia. Without treatment, severe aplastic anemia has a mortality rate exceeding 70% within two years. With modern management, 5-year survival rates now exceed 80% for many patients. Here’s what that management actually looks like.
How Aplastic Anemia Is Diagnosed
Diagnosis starts with a complete blood count (CBC) showing low values across all three cell lines. But low counts alone aren’t enough — you need a bone marrow biopsy to confirm the diagnosis and rule out conditions like myelodysplastic syndrome (MDS) or hairy cell leukemia that can mimic aplastic anemia.
On biopsy, aplastic anemia shows marrow cellularity below 25% (or 25–50% with less than 30% hematopoietic cells), replaced largely by fat. That’s the hallmark finding. Additional workup includes:
- Flow cytometry — to rule out paroxysmal nocturnal hemoglobinuria (PNH), which coexists in up to 50% of cases
- Cytogenetic analysis — to exclude MDS or other clonal disorders
- Telomere length testing — short telomeres suggest inherited bone marrow failure syndromes
- Genetic testing — especially in patients under 40, to screen for Fanconi anemia and other hereditary causes
- Hepatitis serologies and viral panels — hepatitis-associated aplastic anemia accounts for about 5% of cases
Severity Classification: This Drives Everything
Treatment decisions hinge on disease severity. The Camitta criteria classify aplastic anemia into three categories based on blood counts and marrow cellularity:
| Severity | Bone Marrow Cellularity | Blood Count Criteria (at least 2 of 3) |
|---|---|---|
| Non-severe (NSAA) | <25% | Does not meet severe criteria |
| Severe (SAA) | <25% | Neutrophils <500/µL, Platelets <20,000/µL, Reticulocytes <20,000/µL |
| Very severe (vSAA) | <25% | Same as SAA but neutrophils <200/µL |
A patient with non-severe aplastic anemia might be watched or treated with cyclosporine alone. A patient with very severe disease needs aggressive intervention within days — not weeks.
7 Core Medical Procedures and Treatments
1. Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
This is the only curative treatment. For patients under 40 with severe aplastic anemia and a matched sibling donor, upfront transplant is the standard of care. Success rates are impressive: 5-year survival reaches 85–95% with matched sibling donors in younger patients. Outcomes with matched unrelated donors have improved dramatically, now approaching 80% survival in experienced centers.
Conditioning regimens typically use cyclophosphamide with or without anti-thymocyte globulin (ATG). For older patients (over 40–50), transplant-related complications increase, so immunosuppressive therapy is usually tried first.
2. Immunosuppressive Therapy (IST)
The first-line alternative to transplant — and the go-to for patients without a matched sibling donor or those over 40. The classic regimen combines horse ATG (not rabbit — horse ATG showed superior response rates in the landmark NIH trial) with cyclosporine. Response rates hover around 60–70% at 6 months, though relapse occurs in 30–40% of responders over time.
The addition of eltrombopag (a thrombopoietin receptor agonist) to standard IST has been a game-changer. NIH data showed overall response rates jumping to approximately 85–94% when eltrombopag is added upfront, with higher complete response rates than IST alone.
3. Blood Transfusions
Nearly all patients with severe disease require red blood cell and platelet transfusions as supportive care. The goal: keep hemoglobin above 7–8 g/dL and platelets high enough to prevent life-threatening bleeding. However, minimizing transfusions before transplant is critical — heavily transfused patients have higher rates of graft rejection.
4. Iron Chelation Therapy
Chronic transfusions cause iron overload. Once ferritin levels exceed 1,000 ng/mL (roughly after 20+ transfusion units), chelation with deferasirox or deferoxamine becomes necessary to prevent liver and cardiac damage.
5. Growth Factors and Eltrombopag
Eltrombopag isn’t just used alongside IST. In refractory cases, it can stimulate residual stem cells to produce blood cells across all three lineages — not just platelets, despite being a “platelet drug.” The FDA approved it for severe aplastic anemia refractory to IST in 2014.
6. Infection Prophylaxis and Management
With neutrophil counts often below 500/µL, infection is the leading cause of death. Prophylactic antifungals (like voriconazole or posaconazole) and antibacterials are standard. Febrile neutropenia is treated as a medical emergency with broad-spectrum IV antibiotics — typically piperacillin-tazobactam or meropenem, started within an hour.
7. Haploidentical and Alternative Donor Transplants
Only about 25% of patients have a matched sibling donor. For the rest, haploidentical transplants (using a half-matched family member) with post-transplant cyclophosphamide have emerged as a viable option, with 2-year survival rates now exceeding 70% in recent series. This has dramatically expanded transplant access.
Treatment Algorithm at a Glance
| Patient Profile | First-Line Treatment | Second-Line If No Response |
|---|---|---|
| Age <40, matched sibling donor | Allogeneic HSCT | IST + eltrombopag |
| Age <40, no matched sibling | IST + eltrombopag (search for unrelated donor) | Matched unrelated or haploidentical HSCT |
| Age >40 | IST (horse ATG + cyclosporine + eltrombopag) | Alternative donor HSCT or repeat IST |
| Non-severe aplastic anemia | Watch and wait, or cyclosporine ± eltrombopag | Escalate to full IST if counts drop |
When to See a Doctor Immediately
Seek emergency evaluation if you experience:
- Unexplained bruising or petechiae (tiny red/purple dots on the skin)
- Persistent fatigue combined with recurrent infections
- Bleeding that won’t stop — gums, nosebleeds, heavy menstruation
- Fever above 100.4°F (38°C) if you’re already diagnosed with aplastic anemia and have low neutrophil counts
Any combination of low hemoglobin, low platelets, and low white cells on routine bloodwork warrants urgent hematology referral. Don’t accept a “let’s recheck in a month” approach if all three lines are low.
Frequently Asked Questions
Can aplastic anemia be cured completely?
Yes — allogeneic stem cell transplant is curative for most younger patients with a good donor match. Even with immunosuppressive therapy alone, roughly 60–70% of patients achieve meaningful remission, though relapse remains a risk. Adding eltrombopag has pushed those numbers higher.
How long does treatment take to work?
After IST, most patients don’t see meaningful blood count recovery for 3–6 months. Some take up to 12 months. Transplant recovery is faster — engraftment typically occurs within 2–4 weeks, though full immune reconstitution takes 6–12 months.
Is aplastic anemia the same as leukemia?
No. Aplastic anemia is a bone marrow failure disorder — the marrow underproduces cells. Leukemia is a marrow malignancy — the marrow overproduces abnormal cells. However, aplastic anemia carries a long-term risk of evolving into MDS or acute myeloid leukemia (estimated 10–15% over 10 years), which is why ongoing monitoring is essential.
What’s the life expectancy with severe aplastic anemia?
With modern treatment, 5-year survival for severe aplastic anemia is approximately 80–90% for transplanted younger patients and 60–80% for those treated with IST. Without any treatment, severe aplastic anemia is usually fatal within 6–12 months.
Does aplastic anemia run in families?
Most cases (about 75–80%) are acquired, typically from autoimmune attack on the marrow. However, inherited forms like Fanconi anemia, dyskeratosis congenita, and Shwachman-Diamond syndrome account for a meaningful minority — especially in children and young adults. Genetic testing is now recommended for all patients under 40 at diagnosis.
